Research programme: LRRK2 inhibitors - Charles River Laboratories
Latest Information Update: 15 Dec 2015
At a glance
- Originator Charles River Laboratories
- Class Small molecules
- Mechanism of Action LRRK2 protein inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Parkinson's disease
Most Recent Events
- 08 Dec 2015 Early research in Parkinson's disease in USA (unspecified route)